Pluristem (PSTI), Q4/10 Results
February 10th, 2011
No comments
Net loss for Q4/10 was $2.82M or $0.11 based on weighted average shares of 24.9M. Read more…
Archive
Archive for the ‘Stem Cell Technology’ Category
Neuralstem (AMEX:CUR), ALS Clinical Trial includes Endpoints
February 10th, 2011
No comments
CUR updated the progress of its ongoing Phase I clinical trial of the spinal cord stem cells in the treatment of ALS Read more…
Categories: AMEX: CUR, Stem Cell Research, Stem Cell Technology
Aastrom Biosciences (ASTM), WBB initiates Coverage as a SELL
February 9th, 2011
No comments
On 2/9/11, WBB Securities initiated with a SELL rating and a 12 mo price target price of $2.00. Read more…
Categories: NASDAQ: ASTM, Stem Cell Research, Stem Cell Technology, WBB Securities
Neuralstem (CUR), trends up
February 9th, 2011
No comments
CUR as reported on Bloomberg received the FDA’s Orphan Drug Designation Read more…
Categories: AMEX: CUR, Orphan Drug designation, Stem Cell Research, Stem Cell Technology
Geron (GERN), New Leadership Structure
February 9th, 2011
No comments
GERN announced a new leadership structure. Read more…
MotorPlate hESC-Derived Motor Neuron Progenitors Products Launched
February 8th, 2011
No comments
Lonza and California Stem Cell have launched MotorPlate™ Human ESC-derived Motor Neuron Progenitor products. Read more…
Opexa Therapeutics (OPXA), Unit Public Offering of $8.5M
February 8th, 2011
No comments
OPXA priced an underwritten public offering of 4,146,500 units at a price to the public of $2.05 per unit, for gross proceeds of $8.5M. Read more…
Categories: Financing, NASDAQ:OPXA, Stem Cell Research, Stem Cell Technology
Osiris Therapeutics (OSIR) rebounds, Told you so
February 7th, 2011
No comments
OSIR is trading in 2/7/11 mid-day range up $0.36 (5.55%) at $6.85 in a trading range of $6.49 to $6.85 on moderate volume (43,485 versus the 10 day average of 101,933). Read more…
Categories: NASDAQ: OSIR, OSIR Rebounds, Stem Cell Research, Stem Cell Technology
Refocusing Cancer Research, exposing Insidious Stem Cells
February 7th, 2011
No comments
Scientists in Madison, WI have sent blood cells from a leukemia patient back to the embryonic state for the 1st time, opening a window into the early development of the disease Read more…
Categories: leukemia, Refocusing cancer research, Stem Cell Research, Stem Cell Technology
CIRM awards $1.9M to Cedars-Sinai for Spinal Muscular Atrophy (SMA)
February 4th, 2011
No comments
A research team at the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9M grant Read more…
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.